NCT03820531View on ClinicalTrials.gov

DNA-mutation Analysis in Cyst Fluid of Suspected Intraductal Papillary Mucinous Neoplasia of the Pancreas

NACompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions
Pancreas Cyst
Interventions
DIAGNOSTIC_TEST

Next Generation Sequencing

DNA Mutational Analysis in pancreas cyst fluid concerning KRAS/GNAS-mutations and mutations in tumor supressor genes

DIAGNOSTIC_TEST

CEA and lipase

"Measuring CEA and lipase level in pancreas cyst fluid:~CEA \> 192 ng/ml and lipase \> 200 U/l = mucinous cyst"

DIAGNOSTIC_TEST

Cytology

"Cytology in pancreas cyst fluid:~mucinous versus non-mucinous cyst; LGD versus HGD/Carcinoma"

DIAGNOSTIC_TEST

Histology of resected pancreas cyst

Histology of resected pancreas cyst concerning mucinous versus non-mucinous cyst, IPMN versus non-IPMN and LGD versus HGD/Carcinoma

Trial Locations (1)

68165

Tertiary referral hospital: Theresienkrankenhaus und St. Hedwig Hospital, Academic, Mannheim

All Listed Sponsors
collaborator

University Hospital Heidelberg

OTHER

lead

Theresienkrankenhaus und St. Hedwig-Klinik GmbH

OTHER

NCT03820531 - DNA-mutation Analysis in Cyst Fluid of Suspected Intraductal Papillary Mucinous Neoplasia of the Pancreas | Biotech Hunter | Biotech Hunter